Want to stay on top of the science and politics driving biotech today?  Sign up  to get our biotech newsletter in your inbox. The Trump administration is using newly announced 100% tariffs as leverage to push both large and small drugmakers into confidential pricing and manufacturing agreements.
Also, the burgeoning peptide craze is highlighting a trust gap in medicine, in which patients increasingly favor unproven treatments over well-established drugs. Continue to STAT+ to read the full story...
STAT News published a clinical update in Research Highlights on 03 Apr 2026.
The item focuses on STAT+: Biotech investors’ plea to Trump, and a busy M&A week.
Review the original article for the full source wording and details.